The mpn Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mpn Hub cannot guarantee the accuracy of translated content. The mpn and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out moreCreate an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mpn content recommended for you
Myeloproliferative neoplasms (MPN) in the blast phase (BP) are defined as ≥ 20% myeloblasts in the peripheral blood (PB) or bone marrow (BM)—this is seen in around 5–20% of patients with Philadelphia chromosome-negative MPN. The outcomes after allogeneic hematopoietic cell transplantation (HCT) in these patients are still not fully understood.
In this retrospective study, Vikas Gupta and colleagues investigated molecular, cytogenetic, and clinical factors in patients with MPN-BP and their association with outcome post allogeneic HCT.1 Their results have been recently published in Blood Advances and are summarized here.
177 patients with MPN-BP were identified from the Center for International Blood and Marrow Transplant Research database. Next-generation sequencing was possible in only 95 patients (54%), using a panel of 49 genes clinically relevant in hematologic malignancies.
The patients were also analyzed for the following endpoints:
DNA, deoxyribonucleic acid; ET, essential thrombocythemia; HCT, hematopoietic cell transplantation; MPN, myeloproliferative neoplasms; PMF, primary myelofibrosis; PV, primary myelofibrosis. |
|||
|
Sample DNA obtained |
No sample DNA obtained |
Total |
---|---|---|---|
Median age at HCT, years (range) |
59.9 |
58.48 |
58.75 |
Female sex, % |
32.6 |
36.6 |
34.5 |
Karnofsky index < 90%, % |
49.5 |
45.1 |
47.5 |
Type of MPN at diagnosis, % |
|
|
|
Cytogenetics, % |
|
|
|
Graft source, % |
|
|
|
Donor type, % |
|
|
|
References
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content